Author

M. Havenga

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 1 Microbiology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:benchmarking· 1 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1 Research Focus:ecology & biodiversity· 1 Research Focus:gene regulatory network inference· 1 Organism:human· 1

Frequent Co-Authors

A. H. Baker· 1 shared A. J. Pinto· 1 shared A. Lemckert· 1 shared C. van der Zalm· 1 shared G. L. Kajan· 1 shared H. M. van der Schaar· 1 shared J. Custers· 1 shared L. John· 1 shared

Activity by Year

2021-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperImmunology

A. H. Baker

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Reproducible microbial community dynamics of two drinking water systems treating similar source waters.

S. C. Potgieter, Z. Dai, M. Havenga, S. Vosloo, M. Sigudu, A. J. Pinto, S. N. Venter

This study compares microbial community dynamics in two similar drinking water treatment plants and distribution systems, finding reproducible spatial-temporal patterns despite disinfection-induced differences.

bioRxiv · Mar 11, 2021Microbiology

Human AdV-20-42-42, a promising novel adenoviral vector for gene therapy and vaccine product development

M. Z. Ballmann, S. Raus, R. Engelhart, G. L. Kajan, C. van der Zalm, T. Papp, L. John, S. Khan, J. Custers, W. A. M. Bakker, H. M. van der Schaar, N. Arnberg, A. Lemckert, M. Havenga, A. H. Baker

This paper describes the development of a novel adenoviral vector, HAdV-20-42-42, which shows promise for gene therapy and vaccination due to its low seroprevalence and effective transduction capabilities.

bioRxiv · Mar 11, 2021Immunology